ReviewFrontiers in neurology2018
The Glymphatic System in Diabetes-Induced Dementia.
Review in Frontiers in neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Does G-ALPS measure glymphatic function? Revisiting construct validity in diffusion-based glymphatic imaging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Glymphatic system impairment in type II diabetes mellitus adults.Scientific reports · 2026Article
- Cerebral Venous Insufficiency as a Contributing Factor in Dementia: An Emerging Hypothesis.Stroke (Hoboken, N.J.) · 2026Review
- A cross-tissue transcriptome-wide association study identifies novel candidate genes associated with brain glymphatic system function.Molecular brain · 2025Article
- Analysis of ALPS-Index: Difference in Type 2 Diabetes Mellitus With or Without Mild Cognitive Impairment and Its Relationship With Hippocampal Microstructure.Brain and behavior · 2025Article
- Evaluation of the glymphatic system using the DTI-ALPS index in type 2 diabetes mellitus-induced cognitive impairment.Journal of clinical imaging science · 2025Article
- Insights into glymphatic system dysfunction and glucose continuum.World journal of diabetes · 2024Article
- Glymphatic system function in diverse glucose metabolism states.World journal of diabetes · 2024Article
- Modal Analysis of Cerebrovascular Effects for Digital Health Integration of Neurostimulation Therapies-A Review of Technology Concepts.Brain sciences · 2024Article
- Glial cell alterations in diabetes-induced neurodegeneration.Cellular and molecular life sciences : CMLS · 2024Review
- Assessing interstitial fluid dynamics in type 2 diabetes mellitus and prediabetes cases through diffusion tensor imaging analysis along the perivascular space.Frontiers in aging neuroscience · 2024Article
- Peripheral origin exosomal microRNAs aggravate glymphatic system dysfunction in diabetic cognitive impairment.Acta pharmaceutica Sinica. B · 2023Review
- Association of Type 2 Diabetes Mellitus With Perivascular Spaces and Cerebral Amyloid Angiopathy in Alzheimer's Disease: Insights From MRI Imaging.Dementia and neurocognitive disorders · 2023Article
- The role of population-level preventive care for brain health in ageing.The lancet. Healthy longevity · 2023Review
- The consequences of sleep deprivation on cognitive performance.Neurosciences (Riyadh, Saudi Arabia) · 2023Review
- How Organ-on-a-Chip Technology Can Assist in Studying the Role of the Glymphatic System in Neurodegenerative Diseases.International journal of molecular sciences · 2023Review
- Review
- Perspective: Disentangling the effects of tES on neurovascular unit.Frontiers in neurology · 2022Article
- Neurovascular Coupling in Type 2 Diabetes With Cognitive Decline. A Narrative Review of Neuroimaging Findings and Their Pathophysiological Implications.Frontiers in endocrinology · 2022Review
- Breaking barriers: Neurodegenerative repercussions of radiotherapy induced damage on the blood-brain and blood-tumor barrier.Free radical biology & medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The glymphatic system has emerged as an important player in central nervous system (CNS) diseases, by regulating the vasculature impairment, effectively controlling the clearance of toxic peptides, modulating activity of astrocytes, and being involved in the circulation of neurotransmitters in the brain. Recently, several studies have indicated decreased activity of the glymphatic pathway under diabetes conditions such as in insulin resistance and hyperglycemia. Furthermore, diabetes leads to the disruption of the blood-brain barrier and decrease of apolipoprotein E (APOE) expression and the secretion of norepinephrine in the brain, involving the impairment of the glymphatic pathway and ultimately resulting in cognitive decline. Considering the increased prevalence of diabetes-induced dementia worldwide, the relationship between the glymphatic pathway and diabetes-induced dementia should be investigated and the mechanisms underlying their relationship should be discussed to promote the development of an effective therapeutic approach in the near future. Here, we have reviewed recent evidence for the relationship between glymphatic pathway dysfunction and diabetes. We highlight that the enhancement of the glymphatic system function during sleep may be beneficial to the attenuation of neuropathology in diabetes-induced dementia. Moreover, we suggest that improving glymphatic system activity may be a potential therapeutic strategy for the prevention of diabetes-induced dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.